share_log

Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Market Cap Dropped CN¥539m Last Week; Private Companies Bore the Brunt

Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Market Cap Dropped CN¥539m Last Week; Private Companies Bore the Brunt

魯商福瑞達製藥有限公司, Ltd. 's (SHSE: 600223) 上週市值下降了5.39億元人民幣;私營公司首當其衝
Simply Wall St ·  04/16 18:53

Key Insights

關鍵見解

  • Significant control over Lushang Freda PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions
  • 53% of the company is held by a single shareholder (Shandong Commercial Group Co.Ltd)
  • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
  • 私營公司對魯商福瑞達製藥有限公司的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 公司 53% 的股份由單一股東持有(山東商業集團有限公司)
  • 分析師的預測以及所有權數據可以使人們對企業前景有深刻的了解

A look at the shareholders of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) can tell us which group is most powerful. We can see that private companies own the lion's share in the company with 55% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看魯商福瑞達製藥有限公司的股東, Ltd.(上海證券交易所代碼:600223)可以告訴我們哪個集團最強大。我們可以看到,私營公司擁有該公司的大部分股份,所有權爲55%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥539m.

結果,在市值下降5.39億元人民幣之後,私營公司作爲一個整體承受了最大的損失。

In the chart below, we zoom in on the different ownership groups of Lushang Freda PharmaceuticalLtd.

在下圖中,我們放大了魯商弗雷達製藥有限公司的不同所有權群體。

ownership-breakdown
SHSE:600223 Ownership Breakdown April 16th 2024
SHSE: 600223 所有權明細 2024 年 4 月 16 日

What Does The Institutional Ownership Tell Us About Lushang Freda PharmaceuticalLtd?

關於魯商福瑞達製藥有限公司,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

Lushang Freda PharmaceuticalLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Lushang Freda PharmaceuticalLtd's historic earnings and revenue below, but keep in mind there's always more to the story.

魯商福瑞達製藥有限公司已經在股份登記處設立了機構。事實上,他們擁有該公司可觀的股份。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到魯商福瑞達製藥有限公司的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
SHSE:600223 Earnings and Revenue Growth April 16th 2024
SHSE: 600223 2024 年 4 月 16 日的收益和收入增長

We note that hedge funds don't have a meaningful investment in Lushang Freda PharmaceuticalLtd. Our data shows that Shandong Commercial Group Co.Ltd is the largest shareholder with 53% of shares outstanding. This implies that they have majority interest control of the future of the company. In comparison, the second and third largest shareholders hold about 1.7% and 1.1% of the stock.

我們注意到,對沖基金沒有對魯商弗雷達製藥有限公司進行有意義的投資。我們的數據顯示,山東商業集團有限公司是最大股東,已發行股份的53%。這意味着他們對公司的未來擁有多數權益控制權。相比之下,第二和第三大股東持有約1.7%和1.1%的股份。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。

Insider Ownership Of Lushang Freda PharmaceuticalLtd

魯商福瑞達製藥有限公司的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層經營業務,但首席執行官將對董事會負責,即使他或她是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our most recent data indicates that insiders own less than 1% of Lushang Freda Pharmaceutical Co.,Ltd.. However, it's possible that insiders might have an indirect interest through a more complex structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥8.0m worth of shares (at current prices). Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

我們的最新數據顯示,內部人士擁有魯商福瑞達製藥有限公司不到1%的股份。,有限公司。但是,內部人士有可能通過更復雜的結構獲得間接利益。這是一家相當大的公司,因此董事會成員有可能在不擁有太多比例權益的情況下擁有該公司的有意義的權益。在這種情況下,他們擁有價值約800萬元人民幣的股票(按當前價格計算)。可以說,最近的買入和賣出同樣值得考慮。你可以點擊這裏查看內部人士是否在買入或賣出。

General Public Ownership

一般公有制

With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Lushang Freda PharmaceuticalLtd. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

魯商福瑞達製藥有限公司擁有39%的所有權,主要是個人投資者,對魯商福瑞達製藥有限公司有一定程度的影響力。儘管這個群體不一定能做主,但它肯定會對公司的運作方式產生真正的影響。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 55%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有已發行股份的55%。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand Lushang Freda PharmaceuticalLtd better, we need to consider many other factors. For instance, we've identified 1 warning sign for Lushang Freda PharmaceuticalLtd that you should be aware of.

擁有公司股份的不同群體總是值得考慮的。但是,要更好地了解魯商福瑞達製藥有限公司,我們需要考慮許多其他因素。例如,我們已經確定了魯商福瑞達製藥有限公司的一個警告信號,你應該注意這個信號。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但歸根結底,決定這家企業所有者的表現的是未來,而不是過去。因此,我們認爲最好看一下這份免費報告,該報告顯示了分析師是否預測了更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論